A 45-year-old with T2DM and obesity asks about GLP-1 RA vs SGLT2 inhibitor choice. He has ASCVD and no HF/CKD. Which prioritization is reasonable per ...

Question

A 45-year-old with T2DM and obesity asks about GLP-1 RA vs SGLT2 inhibitor choice. He has ASCVD and no HF/CKD. Which prioritization is reasonable per ADA?

Accepted Answer

GLP-1 RA with proven CV benefit prioritized for ASCVD

Answer

SGLT2 must be avoided

Answer

DPP-4 first-line

Answer

Sulfonylurea preferred

Answer

Insulin first for all with ASCVD

us-abfm MCQ (SBA): Diabetes (Agent Selection)

A 45-year-old with T2DM and obesity asks about GLP-1 RA vs SGLT2 inhibitor choice. He has ASCVD and no HF/CKD. Which prioritization is reasonable per ADA?